Terapias con radioligandos (RLT) en España: necesidades no cubiertas y equilibrio entre la oferta y la demanda del Sistema Nacional de Salud
La carga socioeconómica del glioma grado 2 con mutaciones en IDH en España: cuantificación de las pérdidas de productividad de los pacientes y sus cuidadores en España
VOL 10 – NÚM 3 – DICIEMBRE 2025. BIG DATA: ESPACIOS DE DATOS Y SU IMPACTO EN LA EVALUACIÓN ECONÓMICA DE EERR
Carga económica y social de la enfermedad cardiovascular aterosclerótica con enfermedad renal crónica y riesgo inflamatorio en España
El impacto social de la mejora del abordaje de la Enfermedad Ocular Tiroidea en España: Proyecto SROI-EOT 2025
VOL 10 – SUPLEMENTO 1 – JULY 2025. OUTCOME-BASED PAYMENT STRATEGIES AND TECHNOLOGICAL INNOVATION APPLIED TO ORPHAN MEDICINES
Proyecto AGE: Carga socioeconómica y necesidades actuales en la atención a la Atrofia Geográfica en España
Cost per Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons
Proyecto COnEPOC: COALICIÓN EN ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA. Necesidades no cubiertas de la EPOC en España y recomendaciones de mejora
Tight and early HbA1c control in patients with type 2 diabetes mellitus in Spain: quantifying the social value.
Tight and early HbA1c control in patients with type 2 diabetes mellitus in Spain: quantifying the social value
Proyecto ESCRIBO. Estrategia para la Implementación de Cribado y Biomarcadores en el Sistema Nacional de Salud (SNS)
VOL 9 – NÚM 3 – DICIEMBRE 2024. NUEVOS MARCOS EN LA EVALUACIÓN DE TECNOLOGIAS SANITARIAS Y SUS EFECTOS EN MMHH
Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)
Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)
Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)
Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)
Exceso de mortalidad durante la pandemia de COVID-19 en España por causas de fallecimiento no-COVID-19
Recomendaciones para la incorporación efectiva de los pacientes en la evaluación de productos sanitarios
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
Guía de recomendaciones para la identificación y derivación temprana de pacientes con linfoma no Hodgkin de células B candidatos a terapias CAR-T
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimabnin Spain
La utilidad del número necesario de pacientes a largo plazo a tratar para evaluar las terapias inhibidoras de las interleucinas 17 y 23 en el tratamiento de la psoriasis en placas de moderada a grave
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries
Cost Effectiveness Analysis of Tapentadol PR Versus Oxycodone/Naloxone PR in Patients with Musculoskeletal Pain in Spain
Comparative Narrative Review of Oncology Value Assessment Frameworks: Enfortumab Vedotin (EV) for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Budget impact analysis of a transanal irrigation for the treatment of low anterior resection syndrome in Spain
Recommendations from the RET-A Think Tank for the management and implementation of advanced therapies in Spain
Budget IMPACT Analysis of LESS Invasive Surfactant Administration (LISA) Technique As EARLY Rescue Strategy for Preterm Infants with Respiratory Distress Syndrome in Spain
A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 Diabetes Mellitus
Budget impact analysis of low-dose methoxyflurane for the treatment of moderate-to-severe trauma pain in conscious adult patients in Spain
Cost-Utility Analysis of the germline BRCA testing in Women with epithelial ovarian cancer without family history in Spain
Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation
Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain
Coste-efectividad de la polipíldora CNIC frente a los monocomponentes separados en prevención secundaria cardiovascular en España
Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis
